



● THE SOLUTION
FOR PRECISION
MEDICINE

Multi-omics Data and R&D Services to
Decipher Each Patient's Cancer Phenotype

THE GLOBAL MULTI-OMICS SOLUTION FOR PRECISION ONCOLOGY

Indivumed has built a global network with leading cancer clinics to process tissue and blood under identical conditions for assured high quality. Together with structured clinical data, we decipher cancer complexity in each patient in order to develop better drugs and personalize oncology.

Indivumed GmbH's pharmaceutical and biotech customers, as well as clinical partners, benefit from the holistic operations of our three divisions:

Indiv>Type: The unique multi-omics cancer database with clinical partnerships around the globe. Indivumed's quality standards create truly big but also clean and comparable individual cancer data for fast and reliable drug development.

Indiv>uServ: State-of-the-art laboratory services and an unprecedented tumor biobank. Immunohistochemistry services, including multiplex analysis with digital pathology, immune-oncology assays, and access to the Indivumed biobank samples, are among a wide variety of service offerings.

Indiv>uTest: Algorithm-based testing to identify actionable targets for personalized medicine in advanced cancer stages. In particular, a clinically powerful application for patient stratification.





SERVICES IN ONCOLOGY RESEARCH

IndivuServ combines a portfolio of biobank products and customized R&D services. We partner with pharmaceutical, biotech, academia, and IVD leaders for biomarker discovery and drug and CDx development to realize personalized oncology.

High-quality biospecimens

- Cancer biospecimens sets including matched normal tissue.
- Comprehensive clinical data including follow-up and outcome data.
- Mutation characterized samples.
- Liquid biopsy and longitudinal plasma samples with outcome data.
- Access to fresh tissue via our broad clinical network.

Paired with state-of-the-art research services

- IHC assay development and staining services, fluorescent multiplex IHC including digital pathology and chromogenic IHC
- Genomic and proteomic read-outs for expression and mutation status of targets including next generation sequencing, simple western technology, etc.

- Cell biology applications for isolation and characterization to, for example, infiltrate tumor cells.
- Customized research services to meet your oncology R&D needs.

IndivuServ accelerates your development activities and shortens your time-to-market without compromising on quality or clinical data integrity.



PARTNERING FOR PRECISION MEDICINE

Breaking barriers in cancer drug discovery and development: IndivuType is the only global resource that integrates true multi-omics cancer data with clinical information.

This powerful discovery and knowledge platform allows clinicians and the pharmaceutical industry to create and accelerate new insights into cancer biology, leading to better and more affordable drug development for precision medicine and the personalized treatment of cancer.

IndivuType is possible thanks to Indivumed's fifteen years of experience in collecting and curating high-quality, highly controlled, and fully consented cancer biospecimens, obtained from surgical settings through partnerships with leading health-care institutions around the world.

The vast amounts of genomics, transcriptomics, proteomics, phospho-proteomics and immunophenotype imaging information it contains, and the deep and rich clinical and outcome data, are enhanced through machine learning tools and artificial intelligence.

For your benefit

IndivuType's database offers a way to accelerate clinical trials, enable robust protocol design, and generate insights for precision oncology treatment and improved patient outcomes.

We offer our customers from the pharmaceutical and biotech industry and academia the possibility to accelerate their research, by:

- Answering research questions in a well-defined project request.
- Partnering with us in collaborative development projects to fully access IndivuType, our research capabilities (if required with additional biospecimens), and our clinical network.





At Indivumed we are united by a shared responsibility: using our unique expertise and skill sets to work toward individualized cancer diagnosis and treatment for every patient.

Prof. Dr. med. Hartmut Juhl, Founder and CEO Indivumed Group

Indivumed Facts

- Privately held company (GmbH) founded in 2002 in Hamburg (Germany) with two affiliates: Indivumed Inc. (US) and IndivuTest GmbH (Hamburg, Germany).
- Successful history of building a unique global clinical resource for oncology R&D with:
 - Primary access to patients and data in America, Europe, and Asia.
 - Supervised use of identical SOP in all clinics and surgical/pathology suites.
 - Comprehensive and structured clinical data sets.
 - Science driven collection of tissue (frozen, matched tumor/normal, etc.).
- State-of-the-art laboratories in Hamburg (Germany), Frederick, MD (USA), and Singapore.
- World's leading tumor biobank from 50,000 patients with ~1 million biospecimens of identical quality and 50,000 comprehensive and structured clinical data sets.
- Three business divisions operating holistically: IndivuType, IndivuServ, and IndivuTest.



Europe

Indivumed GmbH
Falkenried 88, Bldg. D
20251 Hamburg, Germany

Tel.: +49 (40) 41 33 83 0
Fax: +49 (40) 41 33 83 14
E-mail: info-eu@indivumed.com
www.indivumed.com

North America

Indivumed Inc.
7210 Corporate Court
Ste. E
Frederick, MD 21703

Tel.: +1 (301) 228 9739
E-mail: info-na@indivumed.com
www.indivumed.com